Healthcare Industry News: Stem Cell
News Release - February 7, 2011
Cellerant Therapeutics Announces Key Additions to Sr. Management TeamSAN CARLOS, Calif.--(Healthcare Sales & Marketing Network)-- Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic Stem Cell-based cellular and antibody therapies for blood disorders and cancer, announced that it has strengthened its senior management team with the appointments of Margaret Dillon, Ph.D., as Vice President of Regulatory Affairs and Robert Tressler, Ph.D., as Vice President of Research & Development.
Dr. Dillon joins Cellerant with 19 years of experience in pharmaceutical regulatory affairs. She most recently served as Vice President of Regulatory Affairs at CV Therapeutics Inc. (now Gilead Sciences), where she managed the regulatory affairs group responsible for supporting early through late-stage development activities, including the submission and approval of US and EU marketing applications for two drug products. Dr. Dillon began her regulatory affairs career at Schering-Plough and has held regulatory positions at Connetics Corporation and Systemix Inc., a wholly-owned subsidiary of Novartis. Her regulatory experience spans all phases of clinical development from pre-IND to marketing application approval and commercialization.
Dr. Tressler brings more than 20 years of industry experience in oncology, cardiovascular and immunological indications. He will manage all aspects of Cellerant’s research and development activities, including the Company’s cancer Stem Cell discovery research program. Dr. Tressler most recently served as Executive Director of Research at Geron Corporation where he was responsible for all preclinical discovery research and development, leading to a Phase 2 program targeting cancer Stem Cells. He began his industry career at Syntex (now Roche) and has held leadership positions at Genencor, Chiron, Matrix Pharmaceuticals, Ligand Pharmaceuticals and Glycomed. He is the author and co-author of several patent applications and publications including recent publications related to cancer Stem Cell research.
"We are excited to have both Rob and Margaret join the Cellerant team as we advance CLT-008 in clinical development and expand our discovery research efforts in cancer Stem Cells,” said Ram Mandalam, Ph.D., President and Chief Executive Officer of Cellerant Therapeutics. “Their combined leadership is exceptional and will bring invaluable technical and industry knowledge to the company. We are in a fortunate position to build a world-class research and development team to take our science forward.
“The appointment of Rob extends the Company's experience and expertise in cancer Stem Cell biology, drug discovery and development as we move forward to discover novel drug candidates and advance them into the clinic," said Mandalam. “Margaret brings significant development and commercial regulatory experience spanning multiple therapeutic areas, and including biologics development, which will be crucial as we advance CLT-008 in clinical development.”
About Cellerant Therapeutics
Cellerant Therapeutics is a clinical stage biotechnology company focused on the regulation of the hematopoietic (blood-forming) system. The Company is developing human Stem Cell and antibody therapies for oncology applications and blood-related disorders. Cellerant’s lead product, CLT-008 is currently in Phase 1 clinical trials evaluating safety in patients undergoing cord blood transplantation. The Company is developing CLT-008 as a first-in-class, off-the-shelf, cellular therapeutic for treatment of chemotherapy induced neutropenia, protection from exposure to acute radiation and facilitating cord blood transplantation. The Company also has a cancer Stem Cell (CSC) antibody discovery program focused on therapies for acute myelogenous leukemia, multiple myeloma and myelodysplastic syndrome.
For more information, visit: http://www.cellerant.com.
Source: Cellerant Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.